Humata Health vs Latent
Updated October 23, 2026
Health system prior authorization work tends to fall into two streams: medical services such as imaging and procedures, and the medications that pharmacy teams chase for patients. Humata Health and Latent both automate authorizations with AI, but Humata is built for central teams working imaging, procedure, and drug requests from the order, while Latent is built for pharmacies getting patients onto high-demand and specialty drugs. Knowing which stream causes your longest delays points to the right vendor.
Our analysts compared Humata Health and Latent on focus, appeals, fit for smaller practices, turnaround results, and product depth, using the HIR review of each company and each vendor's own site. In the following sections, we compare them in one table, describe the team each one suits, and cover the news each vendor announced in recent months.
Humata Health vs Latent at a glance, October 2026
| What buyers weigh | Humata Health | Latent |
|---|---|---|
| Pricing model | Custom contract quoted by Humata Health. | A custom contract quoted by Latent. |
| What drives cost | How many authorizations you send, which services are covered (imaging, procedures, drugs, and referrals), the number of hospitals, and EHR connection. | How many medication cases you have, which therapy areas and pharmacies are covered, whether appeals and patient outreach are included, and EHR connection. |
| Main focus | Imaging, procedure, and drug authorizations worked by central teams, starting from the order in Epic. | Medication access for health system pharmacies, including GLP-1 drugs and specialty therapies. |
| Appeals | Not published | Eligibility reviews, authorizations, and appeals run on the same engine. |
| Smaller practices | A standalone web portal for independent practices and specialty clinics, open to an early-access waitlist. | Built for health systems with their own pharmacies. |
| Turnaround results | Scores 8.2 for approvals and staff time saved. | Scores 8.6 for medication access turnaround. Higher score |
| Product depth | Scores 7.8 for its prior authorization product. | Scores 8.1 for its pharmacy access AI. Higher score |
| Getting live | Scores 7.4 for connecting the EHR and payers. | Scores 7.4 for getting EHR and pharmacy workflows live. |
| Time to full value | About 9 to 19 months | About 8 to 17 months |
| What you need first | A leader for the central authorization team. | A pharmacy leader who owns getting patients their drugs. |
| Deal-breaker | You send few authorizations a month. | You have no health system pharmacy. |
| Pricing clarity score | 6.6 | 6.6 |
| HIR overall score | 7.7, Recommend. | 7.9, Recommend. |
| Best for | Health systems with large central authorization teams working imaging, procedure, and drug requests. | Health systems with specialty, retail, or infusion pharmacies that handle many prior authorizations. |
| Not a fit for | Small practices with a few authorizations a week. | Independent practices without a health system pharmacy. |
Which fits which buyer
Find where your authorization backlog sits before you call either vendor.
Choose Humata Health if
- Your central team works imaging and procedure authorizations.
- You run Epic and want requests to start from the order.
- You run an independent practice or clinic and can join the waitlist for its new portal.
Choose Latent if
- Your pharmacies handle many GLP-1 and specialty drug authorizations.
- You want appeals handled by the same system as the first request.
- Your pharmacists will oversee an AI agent's work.
Verdict
Latent scores higher on turnaround and product depth, and fits health systems whose pharmacies carry the authorization load for high-demand drugs. Humata Health fits central authorization teams working imaging, procedure, and drug requests from Epic orders.
Humata buyers should ask how R1's pending acquisition will change contract terms and product plans.
Where the two tools are headed in 2027 and beyond
Humata Health: R1 agreed on August 18, 2026 to acquire Humata Health and fold its prior authorization engine into Phare OS, R1's revenue cycle platform. On June 25, 2026, Humata opened an early-access waitlist for a web portal that grades documentation against payer policies before submission. On June 4, 2026, it joined the CMS Electronic Prior Authorization Acceleration initiative ahead of federal requirements that take effect in 2027.
Latent: Latent announced on September 15, 2026 that seven health systems, including Cleveland Clinic, AdventHealth, and UNC Health, had joined its platform. It also unveiled autonomous clinical agents meant to speed access to GLP-1 drugs and specialty therapies in immunology, rheumatology, and cardiology.
Ask each vendor which of these changes will be in the contract you sign.
Methodology
Each row comes from the HIR reviews of Humata Health and Latent, scored under the HIR method, and from each vendor's public pricing where it exists. Any published price for Humata Health or Latent was checked on that vendor's own site on October 23, 2026.
A green check marks a clear edge for Humata Health or Latent only where their review scores differ by at least 0.3 points or the two reviews show a plain difference. Rows with nothing published for either Humata Health or Latent are left out, and time to full value for each adds up the rollout stages in its review.
Sources
- HIR review of Humata Health and HIR review of Latent
- Humata Health website
- Latent website
- R1 to Acquire Humata Health, August 18, 2026
- Humata Health expands prior authorization technology to independent practices, June 25, 2026
- Humata Health joins CMS Electronic Prior Authorization Acceleration initiative, June 4, 2026
- Latent expands AI platform to unlock access to a new generation of medicines, September 15, 2026